IQVIA Holdings Inc. IQV
Composite 50/100; the shares have moved about 44% annualised. Names that move more contribute more risk for the same amount invested, and our composite reflects how strong the evidence for this one is right now.
Balance-sheet strength ranks 32/100 — a moderate mark against it.
Momentum ranks 84/100 — a strong point in its favour. Quality ranks 54/100 — a slight point in its favour.
Balance-sheet strength ranks 32/100 — a moderate mark against it. Valuation ranks 41/100 — a slight mark against it. Growth ranks 45/100 — a slight mark against it.
What the company does IQVIA Holdings Inc. delivers clinical research, commercial insights, and healthcare intelligence via three segments: Technology & Analytics Solutions, Research & Development Solutions, and Contract Sales & Medical Solutions. Its cloud-based tools and real-world data enable life sciences and healthcare customers to generate evidence, optimize commercial processes, and improve patient outcomes.
Key financials IQVIA reports ROE 22.8%, ROA 5.1%, and ROCE 11.1%. Margins stand at gross 33.0%, operating 13.0%, and net 8.1%. Revenue and EPS growth are 5.9% and 4.8%, respectively. Leverage is high with Debt/Equity 2.58 and Net debt/EBITDA 4.65, while interest coverage is 3.04 and current ratio 0.71.
Stock health Momentum is strong with 3m 57.90%, 6m 61.52%, and 12m 39.09% gains. The stock sits -0.38% below its 52-week high and has an RSI(14) of 72.90. SideraVIA scores Quality 54.2 and Momentum 89.0, but Strength is weak at 31.0 and Valuation at 43.2.
Price vs fair value IQVIA trades at a discount of 5.20% versus the analyst mean target of 275.17. - Analysts highlight retention potential (Zacks 2026-08-26). - Large-cap growth appeal noted (StockStory 2026-08-25). - Momentum tied to AI and CRM themes in sector peers (Zacks/Trefis 2026-08-24).
Looking forward Forward P/E of 18.80 and PEG of 0.32 suggest valuation support, while high leverage and weak Strength score warrant caution. Growth in commercial insights and R&D solutions remains a key driver.
This is not investment advice. Sideravia provides automated, data-driven analysis for information and education only. Nothing on this page is a personal recommendation or an invitation to buy or sell any security, and it does not consider your objectives or financial situation. Assessments are generated by rules applied uniformly to every covered stock — how our scores work.
Data as of 2026-09-04, compiled from third-party sources; errors and delays are possible and figures are not warranted. Investing puts your capital at risk; past performance does not predict future results. We publish our full track record, including the calls that lost, and our conflicts of interest.